Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (34)	12/15/1999 6:34:00 PM
From: WTDEC	Read Replies (1) \| Respond to of 363

biowa, I hate to pose your own question to you but... "2) No mention of NPS-1776 or 1506, or of Allelix neuroscience program? No mention of neuroscience at all..." Oversight? Lowered priority? Giving up? Any thoughts at all? I haven't a clue. Best regards, Walter

To: biowa who wrote (34)	12/15/1999 7:41:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 363

core competencies in metabolic and neurologic diseases A very carefully worded release, trying to convey corporate strategy going forward..... (1) we got biologics!!, we got biologics!!, and (2) we're a "mature" company, planning on following in BCHE's footsteps. So.... they're avoiding research-oriented material in the release, focusing on what analysts and many biotech investors want to hear.... "advanced". And...... they're also pointing to biologics, at a time when it's popular to have them. A merger between two very unproven companies, not enough cash, in two countries? They had to come across as a serious, focused crew. Very nice. Solid feel. Go AMGN! (not saying that I didn't want to hear more about R&D and how it might graduate to preclinical...... need to do lots of homework to comment further, as I certainly don't know this company well)